These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 21475661)
41. Patents and innovation in cancer therapeutics: lessons from CellPro. Bar-Shalom A; Cook-Deegan R Milbank Q; 2002; 80(4):637-76, iii-iv. PubMed ID: 12532643 [TBL] [Abstract][Full Text] [Related]
42. Governing Health Care through Free Choice: Neoliberal Reforms in Denmark and the United States. Larsen LT; Stone D J Health Polit Policy Law; 2015 Oct; 40(5):941-70. PubMed ID: 26195602 [TBL] [Abstract][Full Text] [Related]
43. Inventors as investigators: the ethics of patents in clinical trials. Kimmelman J Acad Med; 2007 Jan; 82(1):24-31. PubMed ID: 17198287 [TBL] [Abstract][Full Text] [Related]
44. Patent and license pearls and pitfalls for taking an idea to the marketplace. Mukharji I J Investig Med; 2011 Jun; 59(5):758-61. PubMed ID: 21441827 [TBL] [Abstract][Full Text] [Related]
45. Financial conflicts of interest in science. Sax JK Ann Health Law; 2012; 21(2):291-327, 6 p preceding i. PubMed ID: 22606918 [TBL] [Abstract][Full Text] [Related]
46. Public vs. proprietary science: a fruitful tension? Eisenberg RS; Nelson RR Acad Med; 2002 Dec; 77(12 Pt 2):1392-9. PubMed ID: 12480650 [TBL] [Abstract][Full Text] [Related]
47. Imaginaries of Invention Management: Comparing Path Dependencies in East and West Germany. Sigl L; Leišytė L Minerva; 2018; 56(3):357-380. PubMed ID: 30147147 [TBL] [Abstract][Full Text] [Related]
48. Intellectual property and biotechnology: the U.S. internal experience--Part I. Brody B Kennedy Inst Ethics J; 2006 Mar; 16(1):1-37. PubMed ID: 16770885 [TBL] [Abstract][Full Text] [Related]
49. Agenda setting for maternal survival in Ghana and Tanzania against the backdrop of the MDGs. Smith SL; Hunsmann M Soc Sci Med; 2019 Apr; 226():135-142. PubMed ID: 30852393 [TBL] [Abstract][Full Text] [Related]
51. Principles and process in the development of the Mayo Clinic's individual and institutional conflict of interest policy. Camilleri M; Gamble GL; Kopecky SL; Wood MB; Hockema ML Mayo Clin Proc; 2005 Oct; 80(10):1340-6. PubMed ID: 16212147 [TBL] [Abstract][Full Text] [Related]
52. District health systems in a neoliberal world: a review of five key policy areas. Segall M Int J Health Plann Manage; 2003; 18 Suppl 1():S5-26. PubMed ID: 14661938 [TBL] [Abstract][Full Text] [Related]
53. Managing the health care market in developing countries: prospects and problems. Broomberg J Health Policy Plan; 1994 Sep; 9(3):237-51. PubMed ID: 10137740 [TBL] [Abstract][Full Text] [Related]
54. [Neoliberal health sector reforms in Latin America: unprepared managers and unhappy workers]. Ugalde A; Homedes N Rev Panam Salud Publica; 2005 Mar; 17(3):202-9. PubMed ID: 15826401 [TBL] [Abstract][Full Text] [Related]
55. Can translational medicine bring us out of the R&D wilderness? Milne CP Per Med; 2009 Sep; 6(5):543-553. PubMed ID: 29783301 [TBL] [Abstract][Full Text] [Related]
56. COVID-19 Digital Health Innovation Policy: A Portal to Alternative Futures in the Making. Bayram M; Springer S; Garvey CK; Özdemir V OMICS; 2020 Aug; 24(8):460-469. PubMed ID: 32511054 [TBL] [Abstract][Full Text] [Related]
57. The dilemmas of incrementalism: logical and political constraints in the design of health insurance reforms. Oliver TR J Policy Anal Manage; 1999; 18(4):652-83. PubMed ID: 10915452 [TBL] [Abstract][Full Text] [Related]
58. Beyond nursing nihilism, a Nietzschean transvaluation of neoliberal values. Krol PJ; Lavoie M Nurs Philos; 2014 Apr; 15(2):112-24. PubMed ID: 24517086 [TBL] [Abstract][Full Text] [Related]
60. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020. Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]